NCT06443177

Brief Summary

The purpose of the study is to see that in addition to existing therapy, how well an additional procedure named spinal cord stimulation might reduce blood vessel spasm from aneurysm rupture.

Trial Health

63
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
25

participants targeted

Target at below P25 for not_applicable

Timeline
12mo left

Started Jul 2026

Geographic Reach
1 country

1 active site

Status
not yet recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 6, 2024

Completed
1 month until next milestone

First Posted

Study publicly available on registry

June 5, 2024

Completed
2.2 years until next milestone

Study Start

First participant enrolled

July 31, 2026

Expected
8 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 31, 2027

4 months until next milestone

Study Completion

Last participant's last visit for all outcomes

July 31, 2027

Last Updated

July 10, 2025

Status Verified

July 1, 2025

Enrollment Period

8 months

First QC Date

May 6, 2024

Last Update Submit

July 9, 2025

Conditions

Keywords

aSAHCVSSympathetic ModulationRuptured brain aneurysm

Outcome Measures

Primary Outcomes (7)

  • Pre-Cerebrovascular response - Velocity

    Pre-SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Pre-Cerebrovascular response - Resistance

    Pre-SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Pre-Cerebrovascular response - Lindegaard ratio

    Pre-SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Post-Cerebrovascular response - Velocity

    Post SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Post-Cerebrovascular response - Resistance

    Post SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Post-Cerebrovascular response - Lindegaard ratio

    Post SCS measures of cerebral blood flow. Subjects will serve as their own internal control (on vs off stimulation) and be grouped collectively to enable more robust statistical analysis. To study the effect of SCS on cerebrovascular tone longitudinally over the course of the vasospasm window, mixed model statistics will be applied.

    Day 1 - Day 14

  • Transcranial Doppler (TCD) velocities of cerebral arteries

    Daily transcranial Doppler studies will be performed to obtain quantitative data on cerebrovascular response during the critical 14-day vasospasm window.

    Day 1 - Day 14

Secondary Outcomes (1)

  • Overall Survival

    Through study completion, approximately 24 months

Study Arms (2)

Spinal Cord Stimulation

EXPERIMENTAL

Participants randomized to receive temporary electrode inserted through the skin into the epidural space of participants upper back/lower neck.

Device: Vectris trial leads and stimulation

Sham Comparator

SHAM COMPARATOR

Participants randomized to not receive temporary electrode.

Device: Sham

Interventions

The electrode is placed into the epidural space using standard epidural placement techniques with paramedian approach. The initial electrode settings have been adopted from prior studies. Should any significant discomfort be elicited from the stimulation, first the amplitude will be decreased to an acceptable level. If an acceptable level of stimulation is unable to be found, the stimulation will be discontinued.

Spinal Cord Stimulation
ShamDEVICE

No electrode is placed.

Sham Comparator

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Provision of signed and dated informed consent form
  • Stated willingness to comply with all study procedures and availability for the duration of the study
  • Diagnosed with Fisher grade 3 or 4 aneurysmal subarachnoid hemorrhage (1)
  • Ability to undergo endovascular treatment of aneurysmal subarachnoid hemorrhage
  • For females of reproductive potential: Negative pregnancy test at time of treatment
  • Plan to undergo standard of care and follow-up

You may not qualify if:

  • Medically unfit to undergo endovascular treatment (e.g., Hunt Hess grade 5)
  • Does not provide consent for the procedure.
  • Posterior circulation aneurysmal subarachnoid hemorrhage.
  • Initial aneurysm treatment after post bleed day 1

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Alabama at Birmingham

Birmingham, Alabama, 35233, United States

Location

MeSH Terms

Conditions

Vasospasm, IntracranialSubarachnoid Hemorrhage

Condition Hierarchy (Ancestors)

Cerebrovascular DisordersBrain DiseasesCentral Nervous System DiseasesNervous System DiseasesVascular DiseasesCardiovascular DiseasesIntracranial HemorrhagesHemorrhagePathologic ProcessesPathological Conditions, Signs and Symptoms

Study Officials

  • Jesse Jones, MD

    University of Alabama at Birmingham

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Jesse Jones, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
SINGLE
Who Masked
PARTICIPANT
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assistant Professor

Study Record Dates

First Submitted

May 6, 2024

First Posted

June 5, 2024

Study Start (Estimated)

July 31, 2026

Primary Completion (Estimated)

March 31, 2027

Study Completion (Estimated)

July 31, 2027

Last Updated

July 10, 2025

Record last verified: 2025-07

Data Sharing

IPD Sharing
Will not share

Locations